心血管疾病与非酒精性脂肪性肝病的共同机制。
Shared Mechanisms between Cardiovascular Disease and NAFLD.
机构信息
NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, San Diego, California.
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
出版信息
Semin Liver Dis. 2022 Nov;42(4):455-464. doi: 10.1055/a-1930-6658. Epub 2022 Aug 25.
Abstract
The burden of nonalcoholic fatty liver disease (NAFLD) is rising globally. Cardiovascular disease is the leading cause of death in patients with NAFLD. Nearly half of individuals with NAFLD have coronary heart disease, and more than a third have carotid artery atherosclerosis. Individuals with NAFLD are at a substantially higher risk of fatal and nonfatal cardiovascular events. NAFLD and cardiovascular disease share multiple common disease mechanisms, such as systemic inflammation, insulin resistance, genetic risk variants, and gut microbial dysbiosis. In this review, we discuss the epidemiology of cardiovascular disease in NAFLD, and highlight common risk factors. In addition, we examine recent advances evaluating the shared disease mechanisms between NAFLD and cardiovascular disease. In conclusion, multidisciplinary collaborations are required to further our understanding of the complex relationship between NAFLD and cardiovascular disease and potentially identify therapeutic targets.
摘要
非酒精性脂肪性肝病（NAFLD）的负担在全球范围内不断增加。心血管疾病是 NAFLD 患者死亡的主要原因。近一半的 NAFLD 患者患有冠心病，超过三分之一的患者患有颈动脉粥样硬化。NAFLD 患者发生致命和非致命心血管事件的风险显著增加。NAFLD 和心血管疾病有多种共同的发病机制，如全身炎症、胰岛素抵抗、遗传风险变异和肠道微生物失调。在这篇综述中，我们讨论了 NAFLD 患者的心血管疾病流行病学，并强调了共同的危险因素。此外，我们还研究了评估 NAFLD 和心血管疾病之间共同发病机制的最新进展。总之，需要多学科合作来进一步了解 NAFLD 和心血管疾病之间复杂的关系，并有可能确定治疗靶点。
相似文献
1
Shared Mechanisms between Cardiovascular Disease and NAFLD.心血管疾病与非酒精性脂肪性肝病的共同机制。
Semin Liver Dis. 2022 Nov;42(4):455-464. doi: 10.1055/a-1930-6658. Epub 2022 Aug 25.
2
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association.非酒精性脂肪性肝病与心血管疾病：因果关系还是关联？
Cardiol Rev. 2024;32(5):453-462. doi: 10.1097/CRD.0000000000000537. Epub 2023 Feb 24.
3
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.非酒精性脂肪性肝病作为人类的一种代谢性疾病：文献综述。
Diabetes Obes Metab. 2021 May;23(5):1069-1083. doi: 10.1111/dom.14322. Epub 2021 Feb 10.
4
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.非酒精性脂肪性肝病的营养补充：一项网状Meta分析。
Cochrane Database Syst Rev. 2021 Jul 19;7(7):CD013157. doi: 10.1002/14651858.CD013157.pub2.
5
Comparative association between NAFLD and MAFLD with cardiovascular events and mortality: Evidence from observational studies.非酒精性脂肪性肝病（NAFLD）和代谢功能障碍相关脂肪性肝病（MAFLD）与心血管事件及死亡率之间的比较关联：来自观察性研究的证据
PLoS One. 2025 Jun 13;20(6):e0312650. doi: 10.1371/journal.pone.0312650. eCollection 2025.
6
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.胰岛素增敏剂治疗非酒精性脂肪性肝病：系统评价。
Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380.
7
Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.非酒精性脂肪性肝病的生活方式干预：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Jun 11;6(6):CD013156. doi: 10.1002/14651858.CD013156.pub2.
8
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.非酒精性脂肪性肝病增加了慢性肾脏病发病的风险：系统评价和荟萃分析。
Metabolism. 2018 Feb;79:64-76. doi: 10.1016/j.metabol.2017.11.003. Epub 2017 Nov 11.
9
A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?系统综述：非酒精性脂肪性肝病患者亚临床心血管疾病的负担和严重程度；我们应该重视吗？
Atherosclerosis. 2013 Oct;230(2):258-67. doi: 10.1016/j.atherosclerosis.2013.07.052. Epub 2013 Aug 9.
10
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
引用本文的文献
1
Atherogenic Combined Index is Independently Associated with MASLD in Type 2 Diabetes: A Cross-Sectional Study.致动脉粥样硬化综合指数与2型糖尿病患者的代谢功能障碍相关脂肪性肝病独立相关：一项横断面研究
Diabetes Metab Syndr Obes. 2025 Aug 25;18:3041-3052. doi: 10.2147/DMSO.S523139. eCollection 2025.
2
Regulating Effect of Weekend Catch-up Sleep on Association of Hepatic Steatosis with Atherosclerotic Cardiovascular Disease.周末补觉对肝脂肪变性与动脉粥样硬化性心血管疾病关联的调节作用
Balkan Med J. 2025 May 5;42(3):233-241. doi: 10.4274/balkanmedj.galenos.2025.2025-1-87.
3
Metabolic dysfunction-associated steatotic liver disease in adults.成人代谢功能障碍相关脂肪性肝病
Nat Rev Dis Primers. 2025 Mar 6;11(1):14. doi: 10.1038/s41572-025-00599-1.
4
Association of Steatotic Liver Disease with Retinal Vascular Occlusion: The Influence of Obesity in a Large Health Screening Cohort.脂肪性肝病与视网膜血管阻塞的关联：肥胖在一个大型健康筛查队列中的影响。
Endocrinol Metab (Seoul). 2025 Apr;40(2):299-303. doi: 10.3803/EnM.2024.2181. Epub 2025 Feb 12.
5
Higher risk of carotid plaque among lean individuals with non-alcoholic fatty liver disease: A retrospective study.非酒精性脂肪性肝病的瘦人颈动脉斑块风险更高：一项回顾性研究。
PLoS One. 2025 Feb 3;20(2):e0316997. doi: 10.1371/journal.pone.0316997. eCollection 2025.
6
The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.肠道微生物群靶向治疗在非酒精性脂肪性肝病中的作用：一项系统评价和网状Meta分析
Front Nutr. 2025 Jan 6;11:1470185. doi: 10.3389/fnut.2024.1470185. eCollection 2024.
7
[Serum indices of hepatic steatosis in indigenous Venezuelan adults of the Piaroa ethnic group].[委内瑞拉皮雅罗阿族成年原住民肝脏脂肪变性的血清指标]
Rev Fac Cien Med Univ Nac Cordoba. 2024 Dec 13;81(4):686-704. doi: 10.31053/1853.0605.v81.n4.44477.
8
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.胰高血糖素样肽-1受体激动剂治疗代谢功能障碍相关脂肪性肝病患者的疗效与安全性：一项随机对照试验的系统评价和荟萃分析
Cureus. 2024 Oct 13;16(10):e71366. doi: 10.7759/cureus.71366. eCollection 2024 Oct.
9
Association Between Noninvasive Liver Fibrosis Scores and Heart Failure in a General Population.非侵入性肝纤维化评分与一般人群中心力衰竭的关系。
J Am Heart Assoc. 2024 Nov 19;13(22):e035371. doi: 10.1161/JAHA.123.035371. Epub 2024 Nov 7.
10
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
本文引用的文献
1
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.2010 年至 2019 年全球肝癌流行病学变化：NASH 是肝癌增长最快的病因。
Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003. Epub 2022 Jun 3.
2
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis.非酒精性脂肪性肝病与结构性心脏、收缩和舒张功能障碍的关联：一项荟萃分析。
Hepatol Int. 2022 Apr;16(2):269-281. doi: 10.1007/s12072-022-10319-6. Epub 2022 Mar 23.
3
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.非酒精性脂肪性肝病相关肝细胞癌的临床特征、监测、治疗分配和结局：系统评价和荟萃分析。
Lancet Oncol. 2022 Apr;23(4):521-530. doi: 10.1016/S1470-2045(22)00078-X. Epub 2022 Mar 4.
4
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.非酒精性脂肪性肝病增加颈动脉粥样硬化和缺血性卒中的风险：一项包含 135602 人的更新荟萃分析。
Clin Mol Hepatol. 2022 Jul;28(3):483-496. doi: 10.3350/cmh.2021.0406. Epub 2022 Mar 2.
5
Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.在非酒精性脂肪性肝病肝硬化中，超声与简化 MRI 最优检查的 HCC 筛查比较效果：一项前瞻性研究。
Aliment Pharmacol Ther. 2022 Apr;55(7):820-827. doi: 10.1111/apt.16844. Epub 2022 Feb 28.
6
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis.2019 年全球非酒精性脂肪性肝病患病率：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2022 Dec;20(12):2809-2817.e28. doi: 10.1016/j.cgh.2021.12.002. Epub 2021 Dec 7.
7
Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis.非酒精性脂肪性肝病与高血压事件风险：系统评价和荟萃分析。
Eur J Gastroenterol Hepatol. 2022 Apr 1;34(4):365-371. doi: 10.1097/MEG.0000000000002299.
8
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.随机、对照试验研究泛 PPAR 激动剂 Lanifibranor 在 NASH 中的作用。
N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.
9
A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease.一项关于非酒精性脂肪性肝病中心血管疾病全球患病率、危险因素和筛查的荟萃分析。
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2462-2473.e10. doi: 10.1016/j.cgh.2021.09.021. Epub 2021 Sep 22.
10
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.随机临床试验：Pemafibrate，一种新型选择性过氧化物酶体增殖物激活受体 α 调节剂（SPPARMα），与安慰剂在非酒精性脂肪性肝病患者中的比较。
Aliment Pharmacol Ther. 2021 Nov;54(10):1263-1277. doi: 10.1111/apt.16596. Epub 2021 Sep 16.
Zotero 插件